Unique ID issued by UMIN | UMIN000003236 |
---|---|
Receipt number | R000003912 |
Scientific Title | Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study. |
Date of disclosure of the study information | 2010/02/26 |
Last modified on | 2018/12/18 08:22:50 |
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.
Japan |
Hypercalcemia with persistent hyperparathyroidism in renal transplant recipients.
Nephrology | Urology |
Others
NO
To evaluate the effect of cinacalcet for hypercalcemia with persistent hyperparathyroidism after renal transplantation by bone-mineral biomarkers and imaging studies of parathyroid glands.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Absolute or relative changes in serum calcium, phosphate and intact-PTH levels.
Absolute or relative changes of parathyroid grands size, bone density, vascular stiffness and bone metabolism markers (vitamin D, FGF23) and safety evaluations (by kidney function, interaction with immunosuppressives)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Cinacalcet Hydrochloride
20 | years-old | <= |
Not applicable |
Male and Female
1.kidney transplant recipient(living or cadaver) at least 6 months after transplantation.
2.Persistent hyperparathyroidism with hypercalcemia [serum intact-PTH greater than 65 pg/ml and corrected serum calcium concentration greater than 10.3 mg/dl by Payne equation cCa = (4- measured albumin)+measured calcium].
3.Stable kidney function with eGFR greater than 30 ml/min/1.73m2 over the last 3 months.
4.No need for change in doses of maintenance immunosuppressive therapy over the last 3 months within target trough levels.
(Cyclosporine:trough 50-150 ng/ml, Tacrolimus:trough 5-10 ng/ml)
5.Agreed to verbal and written informed concent.
1.age below 20 years old or pregnant
2.those who cannot agree to the study
3.inappropriate patients judged by primary or study physicians.
4.history of allergy or severe side effects by cinacalcet
5.those with severe liver dysfunction
6.concomitant use of vitamin D sterols, phosphate binder, calcium supplementation, bisphosphonates
within 2 weeks before start of the study
7.history of parathyroidectomy or percutaneous ethanol injection therapy to parathyroid glands.
15
1st name | |
Middle name | |
Last name | Yugo Shibagaki |
St Marianna University
Nephrology and Hypertension
2-16-1 Sugao Miyamae-ku Kawasaki Kanagawa
044-977-8111
yugoshibagaki@gmail.com
1st name | |
Middle name | |
Last name | Masahiko Yazawa |
St Marianna University
Nephrology and Hypertension
2-16-1 Sugao Miyamae-ku Kawasaki Kanagawa
044-977-8111
masahikoyazawa@marianna-u.ac.jp
St Marianna University
St Marianna University
Other
NO
聖マリアンア医科大学病院(神奈川県)
2010 | Year | 02 | Month | 26 | Day |
Partially published
Completed
2009 | Year | 12 | Month | 02 | Day |
2010 | Year | 03 | Month | 01 | Day |
2012 | Year | 12 | Month | 31 | Day |
2012 | Year | 12 | Month | 31 | Day |
2019 | Year | 08 | Month | 31 | Day |
2019 | Year | 08 | Month | 31 | Day |
2010 | Year | 02 | Month | 22 | Day |
2018 | Year | 12 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003912